About CLL
Here you can learn more about CLL, including current theories relating to disease aetiology and current practice in diagnosis and classification.
Disease background
CLL is numerically the most important leukaemia diagnosis in Western Europe, accounting for around 30% of all leukaemias
Possible factors that may contribute to CLL development
The risk factors for CLL are poorly understood and it is not known whether factors commonly associated with other cancer types such as smoking, diet, exposure to radiation and infections also confer an increased risk of CLL.
Presenting signs and symptoms of CLL
The indolent nature of CLL means that the early stages of the disease can present few or mild symptoms, and that these may be overlooked by the patient
Diagnosis
The International Workshop on CLL (IwCLL) recommends that a diagnosis of CLL is confirmed by haematopathology (blood count and blood smear) and a combination of immunophenotyping and flow cytometric studies to establish the clonality of B lymphocytes
Stages
Clinical staging systems have been developed that classify patients based on their risk profile at presentation
Prognostic factors
Clinical staging is a simple and effective tool for assessing the prognosis of CLL patients
Your feedback is valuable to MabThera
MabThera product characteristics
Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.
- Disclaimer: Mabthera.com is a resource for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.